We found no evidence for a difference in efficacy between hylan and HAs. In view of its higher costs and potential for more local adverse events, we see no rationale for the continued use of hylan in patients with knee OA.
No takes yet. Share an insight, caveat, or question.
Jüni et al. (2007) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: